Ambrx Biopharma to Host Analyst and Investor Day to Discuss ARX788 in Breast Cancer and ARX517 in Prostate Cancer

SAN DIEGO–(BUSINESS WIRE)–Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using its proprietary Engineered Precision Biologics (EPBs) platform to create antibody drug conjugates (ADCs), today announced that it will host a virtual analyst and investor day on February 24 from 12:00pm – 1:00pm ET. The event will feature discussions from oncology experts Hope S. Rugo, M.D., FASCO, (Professor of Hematology and Oncology, Director of Breast Oncology and Clini
Click here to view original post